Navigation Links
Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
Date:4/4/2012

NEW YORK, APRIL 4, 2012 A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or prophylactics available to manage the condition, known as radiation gastrointestinal syndrome (RGS), which is associated with weight loss, vomiting, diarrhea, dehydration, systemic infection, and in extreme cases septic shock and death.

The research was conducted in mice by investigators at Memorial Sloan-Kettering Cancer Center and The University of Texas MD Anderson Cancer Center and will be published in the May 2012 issue of The Journal of Clinical Investigation.

The GI system is maintained through the continuous infusion of epithelial cells produced by specialized stem cells located in gland-like structures called crypts found in the epithelial lining of the small intestines and colon. High-dose irradiation kills these stem cells and destroys the protective epithelial barrier, or mucosa, resulting in onset of RGS within days of exposure.

According to the study, administration of a drug called 2A2 anti-ceramide antibody inhibited cell death (apoptosis) in blood vessels within the GI tract and improved 90-day survival from 0 percent to 80 percent among mice exposed to 15 Gy whole-body irradiation.

"We discovered that using this monoclonal antibody to inhibit blood vessel damage and dysfunction led to a dose-dependent increase in the number of surviving stem cells, which are highly active and responsible for repopulation of the damaged GI epithelium," said the study's corresponding author Richard N. Kolesnick, MD, a member of Memorial Sloan-Kettering's Molecular Pharmacology and Chemistry Program whose laboratory conducted the research experiments.

Developed by investigators at MD Anderson, the drug works by interfering with ceramide a lipid molecule that plays a role in apoptosis generated on the surface of the endothelial cells that make up the smallest blood vessels of a tumor.

The US Department of Health and Human Services has placed significant emphasis on the development and deployment of new therapies and countermeasures to protect first responders, military personnel, and others who are required to enter into areas of potential radiation contamination. Dr. Kolesnick and colleagues are working to develop anti-ceramide antibody as an agent used not only to protect against the damaging effects of radiation prior to exposure, but also to mitigate those effects after exposure.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Antibody treatment protects monkeys from Hendra virus disease
2. Blood Antibody May Signal Start of Ovarian Cancer
3. Specialized regulatory T cell stifles antibody production centers
4. Antibody Finding Might Help in Search for HIV Vaccine
5. Disorderly enzyme is key for antibody diversity
6. Combination antibody therapy shows promise in metastatic melanoma
7. Antibody-guided drug works against acute lymphoblastic leukemia
8. Antibody production gets confused during long-term spaceflight
9. Tiny antibody fragments raised in camels find drug targets in human breast cancer cells
10. Tufts receives patent for antibody treatment against hemolytic uremic syndrome
11. HJF signs distribution agreement for antibody to evaluate prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes ... a mock evacuation of the facility as part of a disaster drill on October ... Hose EMS and Shelton City Emergency Manager, as well as the Connecticut Long ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology: